BIM

117.4

+1.21%↑

SRT3

223.4

-2.15%↓

GXI

58.9

+2.35%↑

ICAD

20.62

-1.43%↓

BIM

117.4

+1.21%↑

SRT3

223.4

-2.15%↓

GXI

58.9

+2.35%↑

ICAD

20.62

-1.43%↓

BIM

117.4

+1.21%↑

SRT3

223.4

-2.15%↓

GXI

58.9

+2.35%↑

ICAD

20.62

-1.43%↓

BIM

117.4

+1.21%↑

SRT3

223.4

-2.15%↓

GXI

58.9

+2.35%↑

ICAD

20.62

-1.43%↓

BIM

117.4

+1.21%↑

SRT3

223.4

-2.15%↓

GXI

58.9

+2.35%↑

ICAD

20.62

-1.43%↓

Search

Orion Oyj (Class B)

Atvērts

54.75 0.83

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

53.7

Max

55.25

Galvenie mērījumi

By Trading Economics

Ienākumi

-12M

61M

Pārdošana

-80M

355M

P/E

Sektora vidējais

21.895

56.294

EPS

0.44

Dividenžu ienesīgums

3.02

Peļņas marža

17.287

Darbinieki

3,943

EBITDA

136M

202M

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

3.02%

2.55%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2B

7.5B

Iepriekšējā atvēršanas cena

53.92

Iepriekšējā slēgšanas cena

54.75

Orion Oyj (Class B) Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 29. apr. 23:53 UTC

Karstas akcijas

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

2025. g. 29. apr. 23:06 UTC

Peļņas

Prudential PLC 1Q New Business Profit Increases by 12%

2025. g. 29. apr. 23:00 UTC

Peļņas

America Movil's Posts Rise in 1Q Profit, Revenue

2025. g. 30. apr. 00:00 UTC

Top Ziņas

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

2025. g. 29. apr. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

2025. g. 29. apr. 23:43 UTC

Tirgus saruna

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

2025. g. 29. apr. 23:41 UTC

Peļņas

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

2025. g. 29. apr. 23:41 UTC

Peļņas

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

2025. g. 29. apr. 23:41 UTC

Peļņas

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

2025. g. 29. apr. 23:24 UTC

Peļņas

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

2025. g. 29. apr. 23:24 UTC

Peļņas

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

2025. g. 29. apr. 23:24 UTC

Peļņas

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

2025. g. 29. apr. 23:24 UTC

Peļņas

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

2025. g. 29. apr. 23:24 UTC

Peļņas

China Vanke 1Q Loss Widened Significantly >000002.SZ

2025. g. 29. apr. 23:15 UTC

Top Ziņas

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

2025. g. 29. apr. 23:14 UTC

Peļņas

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

2025. g. 29. apr. 23:14 UTC

Peļņas

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

2025. g. 29. apr. 23:14 UTC

Peļņas

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

2025. g. 29. apr. 23:14 UTC

Peļņas

China Eastern Airlines 1Q Loss Widened >0670.HK

2025. g. 29. apr. 23:11 UTC

Peļņas

China Southern Airlines Swung to Loss in 1Q>1055.HK

2025. g. 29. apr. 23:11 UTC

Peļņas

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

2025. g. 29. apr. 23:11 UTC

Peļņas

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

2025. g. 29. apr. 23:11 UTC

Peļņas

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

2025. g. 29. apr. 23:11 UTC

Peļņas

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

2025. g. 29. apr. 23:07 UTC

Peļņas

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

2025. g. 29. apr. 23:07 UTC

Peļņas

Air China 1Q Losses Widened>0753.HK

2025. g. 29. apr. 23:07 UTC

Peļņas

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

2025. g. 29. apr. 23:02 UTC

Peļņas

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

2025. g. 29. apr. 23:02 UTC

Peļņas

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

2025. g. 29. apr. 23:02 UTC

Peļņas

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Salīdzinājums

Cenas izmaiņa

Orion Oyj (Class B) Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.